Fractionated Chemotherapy

Fractioned Chemotherapy with a Biological Response Modifier Therapy (FCBRM) is a non-conventional protocol for the treatment of cancer based upon the hypothesis that insulin may be used to potentiate the effectiveness of commonly used anti-cancer drugs. FCBRM uses insulin because cancer cells have many more insulin receptors than healthy cells, and when exposed to insulin, the cancer cells become more susceptible to low doses of chemotherapeutic agents. These agents are given in much lower doses than in conventional therapies because of this insulin effect. FCBRM protocol also calls for the delivery of chemotherapeutic drugs more frequently, to allow a therapeutic impact while minimizing side effects and allowing patients a higher quality of life during treatment.

References

  1. The Anti-Angiogenic Basis of Metronomic Chemotherapy. Kerbel, Kaman, Medscape.com.
  2. Immunomodulatory And Anticancer Effects Of Active Hemicellulose Compound (AHCC). Ghoneum, M., et al., Int. J. Immunotherapy X1(1) 23-28, 1995.
  3. Possible Benefits of Hyperthermia to Chemotherapy.KowalC.D., et al., CANCER RESEARCH 39, 2285-2289, June 1979.
  4. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Hill SM, Blask DE. Cancer Res 1988; 48:6121-6
  5. Cancer Cell Metabolism: Warburg and Beyond; Cancer Cell Metabolism: Warburg and Beyond. Hsu, Peggy P. et al., Cell, Volume 134 , Issue 5 , 703 – 707.
  6. Cancer Stem Cells. Craig T. Jordan, Ph.D., Monica L. Guzman, Ph.D., and Mark Noble, Ph.D. N Engl J Med 2006; 355:1253-1261 September 21, 2006.
  7. Regulation of Cancer Cell Metabolism. The Campbell Family Cancer Research Institute, Toronto, ON M56 2M9, Canada. Nature Reviews Cancer (Impact Factor: 29.54). 02/2011; 11(2):85-95.
  8. Revisiting the ALA/N (a-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases. Berkson, Burton M., et al., Integrative Cancer Therapies.8(4) 416–422, 2009.
  9. CordycepsMushroom : a Potent Anticancer Nutraceutical. Khan; et al; The Open Nutraceuticals Journal, 2010, 3, 179-183.